Table 3 Complications of two cohorts.

From: Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial

Complications (n, %)

PTCy-ATG group (N = 53)

ATG group (N = 51)

P values

Pulmonary infection

19 (35.8)

30 (58.8)

0.019

CMV

27 (50.9)

24 (47.1)

0.692

CMV disease

2 (3.8)

1 (2.0)

0.581

EBV

8 (15.1)

31(60.8)

0.000

PTLD

0 (0.0)

1 (2.0)

0.490

Hemorrhagic cystitis

20 (37.7)

32 (62.7)

0.011

  1. CMV cytomegalovirus, EBV Epstein-Barr virus, PTLD posttransplantation lymphoproliferative disorders.
Back to article page